NCT01228435 2017-12-04
IPI-504 in NSCLC Patients With ALK Translocations
Massachusetts General Hospital
Phase 2 Terminated
Clinical Trials
19 trialsNCT00118092 2017-04-18
17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00118248 2017-02-15
Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00096109 2017-01-16
Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00082966 2015-12-04
Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00779428 2015-10-12
Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin
Bristol-Myers Squibb
Phase 2 Completed
NCT00969917 2015-04-14
Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma
Infinity Pharmaceuticals, Inc.
Phase 2 Withdrawn
NCT00577889 2014-07-25
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00117988 2014-05-30
17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00093496 2014-05-20
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01362400 2014-05-19
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
Infinity Pharmaceuticals, Inc.
Phase 2 Completed
NCT00104897 2013-06-26
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00093405 2013-06-24
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00087386 2013-04-10
Tanespimycin in Treating Patients With Stage III-IV Melanoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00564928 2012-12-11
IPI-504-04
Infinity Pharmaceuticals, Inc.
Phase 2 Completed
NCT00817362 2012-12-11
Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
Infinity Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00627419 2012-12-10
A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma
Infinity Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00088374 2012-07-27
17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00132015 2012-03-15
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed